Continuous Venovenous Hemofiltration Without Anticoagulation

Shigehiko Uchino, Nigel Fealy, Ian Baldwin, Hiroshi Morimatsu, Rinaldo Bellomo

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

We conducted a prospective observational study to assess the efficacy of continuous venovenous hemofiltration (CVVH) with no anticoagulation. A standard anticoagulation protocol for CVVH, which prescribed no anticoagulation for patients at risk of bleeding, was applied to 48 critically ill patients treated with CVVH. Circuit life was prospectively observed, and the following data were obtained for each circuit: heparin use and dose, protamine use, daily prothrombin time-international normalized ratio, activated partial thromboplastin time, and platelet count. Out of 300 consecutive circuits, 143 (47.6%) received no anticoagulation, 31 (10.3%) received regional anticoagulation, and 126 received low dose heparin. No patients experienced bleeding complications secondary to CVVH. Platelet count was significantly lower in the no anticoagulation group (73 x 103/μl) compared with the low dose heparin group (119 x 103/μl) and the protamine group (104 x 103/μl) (p <0.01 for both comparisons). There was no significant difference in mean circuit life among the three groups (heparin, 20.9 hours; no anticoagulation, 19.3 hours; protamine, 21.2 hours; not significant). In conclusion, for a group of patients deemed to be at risk of bleeding, CVVH without anticoagulation achieved an acceptable circuit life, which was similar to that obtained in other patients with low dose heparin anticoagulation or regional anticoagulation with heparin/protamine.

Original languageEnglish
Pages (from-to)76-80
Number of pages5
JournalASAIO Journal
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 2004
Externally publishedYes

Fingerprint

Hemofiltration
Heparin
Protamines
Networks (circuits)
Hemorrhage
Platelets
Platelet Count
International Normalized Ratio
Partial Thromboplastin Time
Prothrombin Time
Thromboplastin
Prothrombin
Critical Illness
Observational Studies
Prospective Studies

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering

Cite this

Continuous Venovenous Hemofiltration Without Anticoagulation. / Uchino, Shigehiko; Fealy, Nigel; Baldwin, Ian; Morimatsu, Hiroshi; Bellomo, Rinaldo.

In: ASAIO Journal, Vol. 50, No. 1, 01.2004, p. 76-80.

Research output: Contribution to journalArticle

Uchino, Shigehiko ; Fealy, Nigel ; Baldwin, Ian ; Morimatsu, Hiroshi ; Bellomo, Rinaldo. / Continuous Venovenous Hemofiltration Without Anticoagulation. In: ASAIO Journal. 2004 ; Vol. 50, No. 1. pp. 76-80.
@article{7d6d010bd2be4ceb8d61278001aa1870,
title = "Continuous Venovenous Hemofiltration Without Anticoagulation",
abstract = "We conducted a prospective observational study to assess the efficacy of continuous venovenous hemofiltration (CVVH) with no anticoagulation. A standard anticoagulation protocol for CVVH, which prescribed no anticoagulation for patients at risk of bleeding, was applied to 48 critically ill patients treated with CVVH. Circuit life was prospectively observed, and the following data were obtained for each circuit: heparin use and dose, protamine use, daily prothrombin time-international normalized ratio, activated partial thromboplastin time, and platelet count. Out of 300 consecutive circuits, 143 (47.6{\%}) received no anticoagulation, 31 (10.3{\%}) received regional anticoagulation, and 126 received low dose heparin. No patients experienced bleeding complications secondary to CVVH. Platelet count was significantly lower in the no anticoagulation group (73 x 103/μl) compared with the low dose heparin group (119 x 103/μl) and the protamine group (104 x 103/μl) (p <0.01 for both comparisons). There was no significant difference in mean circuit life among the three groups (heparin, 20.9 hours; no anticoagulation, 19.3 hours; protamine, 21.2 hours; not significant). In conclusion, for a group of patients deemed to be at risk of bleeding, CVVH without anticoagulation achieved an acceptable circuit life, which was similar to that obtained in other patients with low dose heparin anticoagulation or regional anticoagulation with heparin/protamine.",
author = "Shigehiko Uchino and Nigel Fealy and Ian Baldwin and Hiroshi Morimatsu and Rinaldo Bellomo",
year = "2004",
month = "1",
doi = "10.1097/01.MAT.0000104822.30759.A7",
language = "English",
volume = "50",
pages = "76--80",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Continuous Venovenous Hemofiltration Without Anticoagulation

AU - Uchino, Shigehiko

AU - Fealy, Nigel

AU - Baldwin, Ian

AU - Morimatsu, Hiroshi

AU - Bellomo, Rinaldo

PY - 2004/1

Y1 - 2004/1

N2 - We conducted a prospective observational study to assess the efficacy of continuous venovenous hemofiltration (CVVH) with no anticoagulation. A standard anticoagulation protocol for CVVH, which prescribed no anticoagulation for patients at risk of bleeding, was applied to 48 critically ill patients treated with CVVH. Circuit life was prospectively observed, and the following data were obtained for each circuit: heparin use and dose, protamine use, daily prothrombin time-international normalized ratio, activated partial thromboplastin time, and platelet count. Out of 300 consecutive circuits, 143 (47.6%) received no anticoagulation, 31 (10.3%) received regional anticoagulation, and 126 received low dose heparin. No patients experienced bleeding complications secondary to CVVH. Platelet count was significantly lower in the no anticoagulation group (73 x 103/μl) compared with the low dose heparin group (119 x 103/μl) and the protamine group (104 x 103/μl) (p <0.01 for both comparisons). There was no significant difference in mean circuit life among the three groups (heparin, 20.9 hours; no anticoagulation, 19.3 hours; protamine, 21.2 hours; not significant). In conclusion, for a group of patients deemed to be at risk of bleeding, CVVH without anticoagulation achieved an acceptable circuit life, which was similar to that obtained in other patients with low dose heparin anticoagulation or regional anticoagulation with heparin/protamine.

AB - We conducted a prospective observational study to assess the efficacy of continuous venovenous hemofiltration (CVVH) with no anticoagulation. A standard anticoagulation protocol for CVVH, which prescribed no anticoagulation for patients at risk of bleeding, was applied to 48 critically ill patients treated with CVVH. Circuit life was prospectively observed, and the following data were obtained for each circuit: heparin use and dose, protamine use, daily prothrombin time-international normalized ratio, activated partial thromboplastin time, and platelet count. Out of 300 consecutive circuits, 143 (47.6%) received no anticoagulation, 31 (10.3%) received regional anticoagulation, and 126 received low dose heparin. No patients experienced bleeding complications secondary to CVVH. Platelet count was significantly lower in the no anticoagulation group (73 x 103/μl) compared with the low dose heparin group (119 x 103/μl) and the protamine group (104 x 103/μl) (p <0.01 for both comparisons). There was no significant difference in mean circuit life among the three groups (heparin, 20.9 hours; no anticoagulation, 19.3 hours; protamine, 21.2 hours; not significant). In conclusion, for a group of patients deemed to be at risk of bleeding, CVVH without anticoagulation achieved an acceptable circuit life, which was similar to that obtained in other patients with low dose heparin anticoagulation or regional anticoagulation with heparin/protamine.

UR - http://www.scopus.com/inward/record.url?scp=0347320808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347320808&partnerID=8YFLogxK

U2 - 10.1097/01.MAT.0000104822.30759.A7

DO - 10.1097/01.MAT.0000104822.30759.A7

M3 - Article

VL - 50

SP - 76

EP - 80

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 1

ER -